PerkinElmer Extends Clinical Whole Genome Sequencing Services
September 07 2017 - 8:15AM
Business Wire
Provides Families a Novel, Personalized
Approach to Managing their Health
PerkinElmer, Inc., a global leader committed to innovating for a
healthier world, expanded its Whole Genome Sequencing (WGS)
services to families that preserve their cord blood and cord tissue
with ViaCord. This launch follows the Company’s recent introduction
of its clinical WGS services.
Parents that choose ViaCord, PerkinElmer’s cord blood and cord
tissue preservation business, now have the opportunity to benefit
from a physician-ordered WGS test of their child’s DNA via a simple
saliva test. The test examines a broad range of disease-related
genes and provides diagnostic findings contributing to pediatric
onset diseases. Additionally, the test reports on pharmacogenetic
variants used to optimize certain drug selection.
“WGS is another great opportunity for families to identify and
prepare for important health concerns, positioning themselves to
benefit from the fast moving area of personalized medicine,” said
Morey Kraus, chief scientific officer, ViaCord. “We have seen
tremendous progress using cord blood stem cells to treat disease,
and I expect families who make such health conscious decisions to
benefit from WGS as well. Additionally, with the rapid progress
we’ve seen with regenerative medicine and gene editing, insights
from WGS may be used in the future, in combination with a family’s
cord blood and cord tissue, to optimize the design of a treatment
plan. This is a very exciting next new step in advancing
personalized medicine.”
ViaCord has preserved the umbilical cord stem cells of more than
350,000 newborns and released over 360 cord blood units for
treatment and clinical research studies. It has released more than
200 cord blood units for use in the treatment of nearly 80 diseases
including acute lymphoblastic leukemia and sickle cell disease and
more than 150 cord blood units for use in clinical research studies
including for Cerebral Palsy and Autism Spectrum Disorder.
About PerkinElmerPerkinElmer, Inc. is a global leader
committed to innovating for a healthier world. Our dedicated team
of 9,000 employees worldwide is passionate about providing
customers with an unmatched experience as they help solve critical
issues especially impacting the diagnostics, discovery and
analytical solutions markets. Our innovative detection, imaging,
informatics and service capabilities, combined with deep market
knowledge and expertise, help customers gain earlier and more
accurate insights to improve lives and the world around us. The
Company reported revenue of approximately $2.1 billion in 2016,
serves customers in more than 150 countries, and is a component of
the S&P 500 Index. Additional information is available through
1-877-PKI-NYSE, or at www.perkinelmer.com.
Factors Affecting Future PerformanceThis press release contains
"forward-looking" statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, statements relating to estimates and projections of
future earnings per share, cash flow and revenue growth and other
financial results, developments relating to our customers and
end-markets, and plans concerning business development
opportunities and divestitures. Words such as "believes,"
"intends," "anticipates," "plans," "expects," "projects,"
"forecasts," "will" and similar expressions, and references to
guidance, are intended to identify forward-looking statements. Such
statements are based on management's current assumptions and
expectations and no assurances can be given that our assumptions or
expectations will prove to be correct. A number of important risk
factors could cause actual results to differ materially from the
results described, implied or projected in any forward-looking
statements. These factors include, without limitation: (1) markets
into which we sell our products declining or not growing as
anticipated; (2) fluctuations in the global economic and political
environments; (3) our failure to introduce new products in a timely
manner; (4) our ability to execute acquisitions and license
technologies, or to successfully integrate acquired businesses and
licensed technologies into our existing business or to make them
profitable, or successfully divest businesses; (5) our failure to
adequately protect our intellectual property; (6) the loss of any
of our licenses or licensed rights; (7) our ability to compete
effectively; (8) fluctuation in our quarterly operating results and
our ability to adjust our operations to address unexpected changes;
(9) significant disruption in third-party package delivery and
import/export services or significant increases in prices for those
services; (10) disruptions in the supply of raw materials and
supplies; (11) the manufacture and sale of products exposing us to
product liability claims; (12) our failure to maintain compliance
with applicable government regulations; (13) regulatory changes;
(14) our failure to comply with healthcare industry regulations;
(15) economic, political and other risks associated with foreign
operations; (16) our ability to retain key personnel; (17)
significant disruption in our information technology systems; (18)
our ability to obtain future financing; (19) restrictions in our
credit agreements; (20) the approval of the Brexit Referendum in
the United Kingdom; (21) our ability to realize the full value of
our intangible assets; (22) significant fluctuations in our stock
price; (23) reduction or elimination of dividends on our common
stock; and (24) other factors which we describe under the caption
"Risk Factors" in our most recent quarterly report on Form 10-Q and
in our other filings with the Securities and Exchange Commission.
We disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring
after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170907005488/en/
PerkinElmer, Inc.Brian Willinsky,
+1-781-663-5728brian.willinsky@perkinelmer.com